Shin-Ichiro Miyashita

Dr. Shin-Ichiro Miyashita

Bioindustry, Tokyo University of Agriculture, Tokyo, Japan
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 January 2021 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
SMShin-Ichiro Miyashita
Shin-Ichiro Miyashita
JZJie Zhang
Jie Zhang
SZSicai Zhang
Sicai Zhang
CSCharles Shoemaker
Charles Shoemaker
MDMin Dong
Min Dong
A detoxified chimeric toxin–based platform delivers therapeutics into neurons and has therapeutic effects in mouse models of botulism.

3 February 2023 in Toxins
Verified
Journal Article
Open access
PDF file
SMShin-Ichiro Miyashita
Shin-Ichiro Miyashita
SKShura Karatsu
Shura Karatsu
MFMako Fujiishi
Mako Fujiishi
IHI Hsun Huang
I Hsun Huang
YNYuki Nagashima
Yuki Nagashima
YSYoshimasa Sagane
Yoshimasa Sagane
Botulinum neurotoxin (BoNT), produced by Clostridium botulinum, cleaves proteins involved in neurotransmitter release, thereby triggering flaccid paralyses, which are responsible for botulism. BoNT is classified into seven serotypes (BoNT/A-G); BoNT/A and BoNT/B are used as medical therapeutics and anti-wrinkle reagents. In this study, we investigated the efficacy of BoNT/CD, a mosaic toxin of BoNT/C and BoNT/D, to assess its potential as a therapeutic alternative for BoNT/A. In a cultured neuron assay, BoNT/CD cleaved syntaxin and SNAP-25 with higher efficacy than BoNT/C and BoNT/A. Intramuscularly administrated BoNT/CD induced dose-dependent muscle paralysis, and the paralysis lasted ~21 days in a mouse digit abduction score assay (BoNT/A-induced paralysis lasted ~30 days). BoNT/C failed to induce local paralysis without systemic toxicity. Multiple alignment analyses of the amino acid sequences of the receptor binding domain (HC) of eight BoNT/CDs and two BoNT/Ds showed sequence clustering in five groups. Comparing BoNT/CD strain 003-9 (BoNT/CD003-9) and strain 6813 (BoNT/CD6813) showed that both BoNT/CDs displayed similar efficacies in cultured neurons, but BoNT/CD003-9 displayed higher efficacy in a mouse model than BoNT/CD6813. These findings suggest that BoNT/CD may be a potential alternative for patients who do not respond to existing BoNT-based therapeutics.

18 October 2021 in PLOS Pathogens
Verified
Journal Article
Open access
PDF file
HTHatim Thaker
Hatim Thaker
JZJie Zhang
Jie Zhang
SMShin-Ichiro Miyashita
Shin-Ichiro Miyashita
VCVivian Cristofaro
Vivian Cristofaro
SPSunHyun Park
SunHyun Park
MDMin Dong
Min Dong
Botulinum neurotoxins (BoNTs) are the most potent toxins known and are also utilized to treat a wide range of disorders including muscle spasm, overactive bladder, and pain. BoNTs’ ability to target neurons determines their specificity, potency, and therapeutic efficacy. Homologous synaptic vesicle membrane proteins synaptotagmin-1 (Syt1) and synaptotagmin-2 (Syt2) have been identified as receptors for BoNT family members including BoNT/B, DC, and G, but their contributions at physiologically relevant toxin concentrations in vivo have yet to be validated and established. Here we generated two knockin mutant mouse models containing three designed point-mutations that specifically disrupt BoNT binding in endogenous Syt1 or Syt2, respectively. Utilizing digit abduction score assay by injecting toxins into the leg muscle, we found that Syt1 mutant mice showed similar sensitivity as the wild type mice, whereas Syt2 mutant mice showed reduced sensitivity to BoNT/B, DC, and G, demonstrating that Syt2 is the dominant receptor at skeletal neuromuscular junctions. We further developed an in vivo bladder injection assay for analyzing BoNT action on bladder tissues and demonstrated that Syt1 is the dominant toxin receptor in autonomic nerves controlling bladder tissues. These findings establish the critical role of protein receptors for the potency and specificity of BoNTs in vivo and demonstrate the differential contributions of Syt1 and Syt2 in two sets of clinically relevant target tissues.

27 September 2022 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
IHI-Hsun Huang
I-Hsun Huang
SMShin-Ichiro Miyashita
Shin-Ichiro Miyashita
THTsuyoshi Hata
Tsuyoshi Hata
SKShura Karatsu
Shura Karatsu
KHKeita Hosoya
Keita Hosoya
YSYoshimasa Sagane
Yoshimasa Sagane

11 April 2025 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
IHI Hsun Huang
I Hsun Huang
SMShin-Ichiro Miyashita
Shin-Ichiro Miyashita
YSYoshimasa Sagane
Yoshimasa Sagane